Project Grant R01CA296792
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$680K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
This Project Grant award, ID P50CA275741, was provided by the National Cancer Institute (NCI) under the Cancer Centers Support Grants program (CFDA 93.397). The $4,408,316 award to the University of California, San Francisco (UCSF) aims to address the significant public health burden of prostate cancer through translational research across four key objectives: Investigate molecular drivers of aggressive prostate cancer Develop biomarkers to guide treatment of advanced prostate cancer Target...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
This Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,199,514 to develop a comprehensive and scalable multimodal AI model, termed "PRECISE", that fuses imaging and non-imaging data to enable early detection of pancreatic ductal adenocarcinoma (PDAC). The project aims to create deep learning models that can segment imaging biomarkers from abdominal CT scans and combine them with clinical data...
This Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Metastx LLC, a small business located in Pittsburgh, PA, provides $399,954 in funding from Jul 1, 2025 to Jun 30, 2026. The project aims to develop a novel predictive model for metastatic potential in early-stage prostate cancer patients by integrating epithelial-mesenchymal transition signature markers with advanced imaging and machine learning techniques. The goal is to...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Regents of the University of Michigan aims to develop a real-time functional photoacoustic imaging platform to accurately detect and characterize the aggressiveness of prostate cancer. The $568,151 award, effective February 3, 2025 through January 31, 2030, will support the optimization of photoacoustic contrast agents, evaluation of the imaging platform in mouse models, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalized treatment planning of Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy (RPT) for metastatic castration-resistant prostate cancer. The project aims to leverage imaging data from pre-treatment PSMA-PET scans and during-treatment SPECT scans to build predictive models that can estimate...
This federal Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of an AI-powered system to enhance the detection and tracking of metastatic colorectal cancer using computed tomography (CT) imaging. The $718,456 award, with a project period from July 1, 2025 to May 31, 2029, will enable researchers at the...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...